Biotech Hangout podcast artwork
Science

Biotech Hangout

by Daphne Zohar, Josh Schimmer, Brad Loncar, Tim Opler and more

Today: #187 in Science on our combined chart.

Share this ranking Claiming needs an RSS feed. Contact us.
Listen on Apple PodcastsOvercast

Chart positions today

Science
#187 New on this chart
#170 Pulse 3

If you like Biotech Hangout, try…

Ranking history

History builds daily. We started tracking this show on the Science chart recently, so the trend line appears after a second day of data.
View as table
DateApple Podcasts
Oct 3#170

About the show

A weekly discussion of all things biotech – breaking news, data, deals, and FDA actions – with a community of biotech industry leaders and experts. Join the live streams hosted by @BiotechCH, @daphnezohar, @bradloncar and @biotech1 on Twitter Spaces every Friday at 12pm ET.

Latest episodes

  • Episode 198 - October 2, 2026

    October 2, 2026 · 1 hr 0 min

    On this week's episode, Graig Suvannavejh, Sam Fazeli, Eric Schmidt, and Brian Skorney open with a look at the public markets, noting the XBI is up 27% year-to-date but down about 9% since its August high. The co-hosts then touched on…

  • Episode 197 - September 25, 2026

    September 25, 2026 · 59 min

    On this week's episode, Sam Fazeli, Yaron Werber, Brian Skorney, and Matt Gline open with the IPO market, noting record average raise sizes even as XBI softens. The group turns to policy, unpacking newly FOIA-disclosed details of Pfizer's…

  • Episode 196 - September 18, 2026

    September 25, 2026 · 55 min

    On this week's episode, Josh Schimmer, Eric Schmidt, Paul Matteis, and guest Adam Feuerstein open with the OpenAI/Hugging Face AI agent controversy, debating whether calls for AI regulation reflect genuine safety concern or capital…

  • Episode 195 - September 11, 2026

    September 15, 2026 · 1 hr 0 min

    On this week's episode, Tess Cameron, Brian Skorney, Paul Matteis, and Yaron Werber open with a look at markets, noting the XBI slipped just over 3% amid concerns about energy prices, inflation, and long-term U.S. fiscal health weighing on…

  • Episode 194 - August 28, 2026

    August 28, 2026 · 1 hr 2 min

    On this week's episode, Daphne Zohar, Eric Schmidt, Sam Fazeli, and Graig Suvannavejh open with a strong week for biotech, partially driven by M&A, noting it's already past 2025's full-year total. The group turns to Moderna, whose melanoma…

  • Episode 193 - August 14, 2026

    August 14, 2026 · 59 min

    On this week's episode, Chris Garabedian, Graig Suvannavejh, Paul Matteis, and Tess Cameron open with the biotech market. They describe 2026 as strong but discerning, with 19 Nasdaq IPOs this year and generalist investors still not fully…

  • Episode 192 - August 7, 2026

    August 7, 2026 · 1 hr 4 min

    On this week’s episode, Sam Fazeli, Brian Skorney, Yaron Werber, and Strand Therapeutics CEO Jake Becraft open with the wave of dealmaking and a solid Q2 earnings season, then turn to the reports of the potential AstraZeneca/Bristol Myers…

  • Episode 191 - July 31, 2026

    August 3, 2026 · 1 hr 0 min

    On this week's episode, Graig Suvannavejh, Tim Opler, Yaron Werber, Paul Matteis, and Brian Skorney kicked off with a review of the market, noting pressure in the XBI despite a longer-term bounce-back from trough levels, though they see…